David E. Olson, Ph.D.
Director
John A. Gray, M.D., Ph.D.
Associate Director
A Letter from our Directors
This season brings continued momentum for the IPN, as researchers across our community tackle nuanced questions about safety, mechanism, and impact while pushing neurotherapeutic science forward.
Highlights in this issue range from clinical insight to molecular innovation; from examining psilocybin use during the postpartum period, to using light-driven chemistry to create psychedelic-inspired molecules without hallucinations. New findings linking brain choline levels to anxiety further emphasize the role of foundational neuroscience in shaping future mental health treatments.
We’re also excited to share updates from the inaugural year of our Pilot Grant Program, which supports bold, early-stage ideas across disciplines, as well as celebrate recent honors earned by our faculty affiliates that reflect the growing reach of IPN research.
Finally, we’re proud to see IPN science reaching broader audiences, including a recent FOX40 feature highlighting advances in non-hallucinogenic psychedelic-inspired compounds like JRT.
As always, thank you for being part of the IPN community and for supporting research aimed at transforming how we understand and treat brain disorders.
Sincerely,
Director David E. Olson and Associate Director John A. Gray
Psilocybin and Postpartum Risk
Shining Light on Life’s Building Blocks
Choline, Anxiety, and the Brain
Pilot Grants Fuel New Ideas
Affiliate Excellence in Action
IPN’s FOX40 Feature
